Latest News About - biological derived devices

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Monday, September 16, 2019

3:05:00 AM CEST

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
nl
no
pap
pl
ps
pt
ro
ru
rw
se
si
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Quotes... Extracted quotes

John Jensen said: “We are excited to partner with Bioxytran and to assist the company in achieving its strategic, operating and financial objectives” “Bioxytran represents an opportunity to exploit many applications for its molecule that delivers oxygen to the brain. Bioxytran has the potential to create value by enhancing its investor base through an understanding of the various applications that Bioxytran seeks to exploit with its molecule” External link

4-traders Friday, September 13, 2019 9:09:00 PM CEST

David Platt added (about John Jensen): “We anticipate that Jensen and Huddie will be able to communicate the Bioxytran story effectively. Their expertise and experience in both investment banking and entrepreneurial ventures, in the healthcare sector in general and biotechnology in particular, will assist Bioxytran in a number of areas including working with us to optimize the timing of our regulatory initiatives. We are happy to welcome Jensen and Huddie to our Advisory Board” External link

4-traders Friday, September 13, 2019 9:09:00 PM CEST

David M Reese said: "The potential to combine KYPROLIS with DARZALEX, two powerful targeted agents, represents an additional therapeutic approach for patients with relapsed or refractory multiple myeloma," External link

markets-businessinsider Friday, September 13, 2019 3:13:00 PM CEST

Sandra Horning said: "With this single injection under the skin, people with HER2-positive breast cancer receiving Perjeta and Herceptin can have a faster treatment option," External link

finanznachrichten-en Friday, September 13, 2019 7:35:00 AM CEST

Amy Abernethy explicó: "Aunque la incidencia total de LACG parece relativamente baja, una vez que los datos han señalado que el producto parece directamente vinculado a problemas graves en los pacientes , incluida la muerte, la FDA alertó a la compañía sobre la necesidad de una retirada" External link

semana Friday, July 26, 2019 4:24:00 AM CEST

Most associated names

Daily number of articles in this category

Trend data not available for this selection.